Dudediligence.

Exelixis, Inc

EXELNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$568.3MJun ’25$597.8MSep ’25$597.8MOct ’25$598.7MDec ’25$598.7MJan ’26$610.8MMar ’26$610.8MApr ’26$628.7MJul ’26
Net income, by quarter
$184.8MJun ’25$193.6MSep ’25$193.6MOct ’25$244.5MDec ’25$244.6MJan ’26$210.5MMar ’26$210.5MApr ’26$212.1MJul ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Jan 2026
Revenue$1.43B$1.61B$1.83B$2.17B$2.32B
Gross profit$1.38B$1.55B$1.76B$2.09B$2.24B
Operating income$286.7M$201.5M$170.9M$604.6M$872.2M
Net income$231.1M$182.3M$207.8M$521.3M$782.6M
Operating cash flow$400.8M$362.6M$333.3M$700.0M$884.3M
Free cash flow$346.6M$334.9M$292.9M$671.5M$875.8M
Cash$647.2M$501.2M$263.0M$217.4M$482.5M
Shares outstanding318.8M324.0M302.8M281.7M262.5M